Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0476 Long-term Study in Perennial Allergic Rhinitis
NCT00771160Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Sep 2004
- Primary completion
- Feb 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of montelukast in perennial allergic rhinitis (PAR) (2 arms), sponsored by Organon & Co. Primary endpoint: Any clinical or laboratory adverse experience at 12 weeks. Started Sep 2004; status: completed.
02
Drugs
montelukast
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT00771160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00771160.